Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 6/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535155 | 1.00 | NNMT (0.62) | NNMTGSK3BMKNK1MKNK2MAPT | |
| Bromide SCHEMBL6116910 | 0.98 | NNMT (0.60) | NNMTGSK3BMKNK1MKNK2MAPT | |
| SCHEMBL18397122 | 0.85 | MAPT (0.68) | NNMTGSK3BMAPTPTPN1 | |
| SCHEMBL2186062 | 0.84 | NNMT (0.64) | NNMTMKNK1MKNK2MAPTMEN1 | |
| SCHEMBL30543017 | 0.84 | NNMT (0.64) | NNMTMKNK1MKNK2MAPTMEN1 | |
| SCHEMBL18397028 | 0.84 | MAPT (0.46) | NNMTGSK3BMAPTPTPN1 | |
| SCHEMBL21741497 | 0.83 | NNMT (0.62) | NNMTMKNK1MKNK2MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL30461874 | 0.83 | NNMT (0.62) | NNMTMKNK1MKNK2MAPTMEN1 | |
| SCHEMBL9670872 | 0.83 | NNMT (0.62) | NNMTGSK3BMKNK1MKNK2MAPT | |
| Hydrochloric Acid SCHEMBL9753848 | 0.81 | NNMT (0.65) | NNMTMKNK1MKNK2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-110183431-B | Compound for treating or preventing liver diseases | 江苏新元素医药科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115279741-A | 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders | 医肯纳肿瘤学公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-107922396-B | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-4031531-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787135-A | Substituted imidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | NNMT 2677/4885GSK3B 890/4885MKNK1 251/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | NNMT 2677/4885GSK3B 890/4885MKNK1 251/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | NNMT 2677/4885GSK3B 890/4885MKNK1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.